PHI with Echinococcus granulosus infection of other organs
How does this condition affect your private health insurance?
Echinococcus granulosus infection (cystic echinococcosis, CE) is a parasitic zoonosis. Humans contract it by ingesting *Echinococcus granulosus* eggs from infected dog feces. Larvae hatch, penetrate gut, disseminate, forming slow-growing hydatid cysts. Liver and lungs are common, but CE in "other organs" like spleen, kidneys, bones, brain, or heart also occurs. Cysts often remain asymptomatic for years. Symptoms arise from mass effect, compression, or rupture, potentially causing severe anaphylactic reactions. Diagnosis involves imaging, serology. Treatment combines surgery with prolonged antiparasitic medication.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Years, often asymptomatic for a long period, with symptoms developing gradually.
Duration of Illness (Lifetime)
Chronic, progressive disease if untreated; can be lifelong with potential for recurrence even after treatment.
Cost of Treatment (Initial)
High, involving diagnostics (imaging, serology), potential surgery, and prolonged antiparasitic drug therapy.
Cost of Treatment (Lifetime)
Very high, especially if multiple surgeries, long-term medication, or management of complications are required.
Mortality Rate
Low to moderate, significantly increased with cyst rupture, anaphylaxis, or vital organ involvement if untreated or poorly managed.
Risk of Secondary Damages
High, including organ dysfunction due to mass effect, anaphylaxis from cyst rupture, secondary cyst dissemination, neurological deficits (CNS cysts), and bone destruction (bone cysts).
Probability of Full Recovery
Moderate to high for single, resectable cysts with appropriate treatment. Lower for multiple, disseminated, or inaccessible cysts, and recurrence is possible.
Underlying Disease Risk
Low. The disease is primarily acquired through environmental exposure; not strongly linked to specific underlying medical conditions, though immunosuppression might influence progression.